{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:09:55Z","timestamp":1785247795824,"version":"3.55.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Clinical trials indicate that acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, is safe and effective for treating patients with chronic lymphocytic leukemia (CLL), but real-world evidence on its clinical effectiveness is limited. This ongoing multicenter retrospective chart review included UK adults with previously untreated CLL who received acalabrutinib monotherapy as part of a UK-wide early access program. These patients received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021. Data from 282 patients (male patients, n = 156 [55%]) collected from 29 sites across the United Kingdom revealed a median age of 73.9 years (interquartile range [IQR], 68.6-79.4) at acalabrutinib initiation (index date) and a median time of 3.0 years (IQR, 1.2-5.7; n = 281) from CLL diagnosis to treatment. The median follow-up was 48.9 months (IQR, 45.0-52.3). At the 3-year landmark, real-world progression-free survival was 82.5% (95% confidence interval [CI], 78.2-87.1), and real-world overall survival was 84.3% (95% CI, 80.2-88.7). Additionally, 72.3% of patients (95% CI, 67.3-77.8) remained on acalabrutinib treatment. The most common reasons for acalabrutinib discontinuation were adverse events (AEs; 31\/87 [36%]), death (16\/87 [18%]), and disease progression (14\/87 [16%]). Of the 270 patients with recorded information, 99 patients (37%) experienced \u22651 prespecified AE, of which the most frequent were upper respiratory tract infection (n = 21 patients [8%]), rash (n = 13 [5%]), and neutropenia (n = 12 [4%]). This study adds to a body of clinical trial and further postmarketing evidence demonstrating the effectiveness and safety of acalabrutinib within routine UK clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019978","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:54:47Z","timestamp":1777488887000},"page":"4873-4883","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"first","affiliation":[{"name":"1Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5184-9464","authenticated-orcid":false,"given":"Nicolas","family":"Martinez-Calle","sequence":"additional","affiliation":[{"name":"2Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-011X","authenticated-orcid":false,"given":"Shankara","family":"Paneesha","sequence":"additional","affiliation":[{"name":"3Department of Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Norouzi","sequence":"additional","affiliation":[{"name":"4Department of Haematology, James Cook University Hospital, Middlesbrough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-4111","authenticated-orcid":false,"given":"David","family":"Tucker","sequence":"additional","affiliation":[{"name":"5Royal Cornwall Hospital NHS Trust, Treliske, Truro, Cornwall, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2618-711X","authenticated-orcid":false,"given":"Harriet","family":"Walter","sequence":"additional","affiliation":[{"name":"6Leicester Royal Infirmary, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Boden","sequence":"additional","affiliation":[{"name":"7United Lincolnshire Hospitals NHS Trust, Lincoln, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Kilner","sequence":"additional","affiliation":[{"name":"8Department of Haematology, North Tyneside General Hospital, North Shields, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Phillips","sequence":"additional","affiliation":[{"name":"9Department of Haematology, University Hospitals of North Midlands Trust, Stoke-on-Trent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3320-3034","authenticated-orcid":false,"given":"Piers E.M.","family":"Patten","sequence":"additional","affiliation":[{"name":"10Comprehensive Cancer Centre, King\u2019s College London, London, United Kingdom"},{"name":"11Department of Haematology, King\u2019s College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimish","family":"Shah","sequence":"additional","affiliation":[{"name":"12Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghna","family":"Ruparelia","sequence":"additional","affiliation":[{"name":"13Royal Derby Hospital, Derby, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Oddy","sequence":"additional","affiliation":[{"name":"14Department of Haematology, Mid Yorkshire Teaching Hospital NHS Trust, Wakefield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tan","family":"Tsawayo","sequence":"additional","affiliation":[{"name":"15East Sussex Healthcare NHS Trust, East Sussex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2211-1831","authenticated-orcid":false,"given":"Francesco","family":"Forconi","sequence":"additional","affiliation":[{"name":"16Southampton General Hospital, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Wardle","sequence":"additional","affiliation":[{"name":"17University Hospital of North Tees, Stockton-on-Tees, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobore","family":"Gbemre","sequence":"additional","affiliation":[{"name":"18Doncaster and Bassetlaw Teaching Hospitals NHS Trust, Doncaster, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Gregory","sequence":"additional","affiliation":[{"name":"19Department of Haematology, Royal Albert Edward Infirmary, Wigan, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Cook","sequence":"additional","affiliation":[{"name":"20Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Allsup","sequence":"additional","affiliation":[{"name":"21Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Morris","sequence":"additional","affiliation":[{"name":"22Dorset County Hospital NHS Trust, Dorchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Knechtli","sequence":"additional","affiliation":[{"name":"23Royal United Hospital NHS Foundation Trust, Bath, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Davies","sequence":"additional","affiliation":[{"name":"24University Hospital of Wales, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Galani","sequence":"additional","affiliation":[{"name":"25Department of Haematology, Darent Valley Hospital, Dartford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marr","sequence":"additional","affiliation":[{"name":"26Freeman Hospital, Newcastle, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2314-6558","authenticated-orcid":false,"given":"Claire","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"27University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Williams","sequence":"additional","affiliation":[{"name":"28Department of Haematology, Clatterbridge Cancer Centre, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Hickey","sequence":"additional","affiliation":[{"name":"29OPEN Health, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Harding","sequence":"additional","affiliation":[{"name":"30AstraZeneca, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhjit","family":"Hunjan","sequence":"additional","affiliation":[{"name":"30AstraZeneca, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina T.","family":"Blak","sequence":"additional","affiliation":[{"name":"30AstraZeneca, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5693-2789","authenticated-orcid":false,"given":"Renata","family":"Walewska","sequence":"additional","affiliation":[{"name":"31Cancer Care, University Hospitals Dorset, Bournemouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"2","key":"2026072809370882400_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.hoc.2013.01.002","article-title":"Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications","volume":"27","author":"Herishanu","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026072809370882400_bib2","unstructured":"Cancer Research UK\n          . Chronic Lymphocytic Leukaemia (CLL) Statistics. Accessed 29 April 2025. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-cll."},{"key":"2026072809370882400_bib3","unstructured":"American Cancer Society\n          . Typical Treatment of CLL. Accessed 29 April 2025. https:\/\/www.cancer.org\/cancer\/types\/chronic-lymphocytic-leukemia\/treating\/treatment-by-risk-group.html."},{"issue":"12","key":"2026072809370882400_bib4","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2026072809370882400_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-3-4","article-title":"Ibrutinib for B cell malignancies","volume":"3","author":"Novero","year":"2014","journal-title":"Exp Hematol Oncol"},{"key":"2026072809370882400_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-015-0165-x","article-title":"Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia","volume":"8","author":"Rai","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"S3","key":"2026072809370882400_bib7","doi-asserted-by":"crossref","first-page":"e944666d","DOI":"10.1097\/01.HS9.0000969512.94466.6d","article-title":"P652: improved survival of patients with chronic lymphocytic leukemia between 1998-2022, including the era of target therapies with BCL2 and BTK inhibitors","volume":"7","author":"Tadmor","year":"2023","journal-title":"HemaSphere"},{"issue":"1","key":"2026072809370882400_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2026072809370882400_bib9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2026072809370882400_bib10","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2026072809370882400_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"25","key":"2026072809370882400_bib12","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026072809370882400_bib13","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2023-174913","article-title":"Analysis of ventricular arrhythmias and sudden death with acalabrutinib from 5 prospective clinical trials","volume":"142","author":"Sharman","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2026072809370882400_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10232","key":"2026072809370882400_bib15","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"24","key":"2026072809370882400_bib16","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment-naive chronic lymphocytic leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026072809370882400_bib17","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2026072809370882400_bib18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"2026072809370882400_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026072809370882400_bib20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN","volume":"146","author":"Sharman","year":"2025","journal-title":"Blood"},{"key":"2026072809370882400_bib21","unstructured":"National Institute for Health and Care Excellence (NICE)\n          . Acalabrutinib for Treating Chronic Lymphocytic Leukaemia. Accessed 21 August 2025. https:\/\/www.nice.org.uk\/guidance\/ta689\/chapter\/1-Recommendations."},{"key":"2026072809370882400_bib22","unstructured":"Scottish Medicines Consortium\n          . Acalabrutinib (Calquence). Accessed 21 August 2025. https:\/\/scottishmedicines.org.uk\/medicines-advice\/acalabrutinib-calquence-full-smc2347\/."},{"key":"2026072809370882400_bib23","unstructured":"Scottish Medicines Consortium\n          . Acalabrutinib (Calquence). Accessed 21 August 2025. https:\/\/scottishmedicines.org.uk\/medicines-advice\/acalabrutinib-calquence-abb-smc2346\/."},{"key":"2026072809370882400_bib24","unstructured":"Health Research Authority (HRA)\n          . Guidance for Using Patient Data. Accessed 8 July 2025. https:\/\/www.hra.nhs.uk\/covid-19-research\/guidance-using-patient-data\/."},{"issue":"25","key":"2026072809370882400_bib25","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2026072809370882400_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood.2024028064","article-title":"International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations","volume":"146","author":"Kittai","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026072809370882400_bib27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2023-182114","article-title":"Outcomes of patients with Richter transformation without prior chemoimmunotherapy for CLL\/SLL: an international multicenter retrospective study","volume":"142","author":"Kittai","year":"2023","journal-title":"Blood"},{"issue":"16","key":"2026072809370882400_bib28","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/bloodadvances.2023009739","article-title":"Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia","volume":"7","author":"Roeker","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026072809370882400_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fon-2023-0436","article-title":"Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib","volume":"20","author":"Jacobs","year":"2024","journal-title":"Future Oncol"},{"issue":"2","key":"2026072809370882400_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.36401\/JIPO-21-12","article-title":"Acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukemia: a meta-analysis of randomized controlled trials","volume":"5","author":"Htut","year":"2022","journal-title":"J Immunother Precis Oncol"},{"issue":"11","key":"2026072809370882400_bib31","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1007\/s00277-024-05921-7","article-title":"Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis","volume":"103","author":"Nunes","year":"2024","journal-title":"Ann Hematol"},{"key":"2026072809370882400_bib32","unstructured":"Department of Health & Social Care\n          . Defining the Highest-Risk Clinical Subgroups Upon Community Infection With SARS-CoV-2 When Considering the Use of Neutralising Monoclonal Antibodies (nMABs) and Antiviral Drugs: Independent Advisory Group Report. Accessed 3 July 2025. https:\/\/www.gov.uk\/government\/publications\/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report\/defining-the-highest-risk-clinical-subgroups-upon-community-infection-with-sars-cov-2-when-considering-the-use-of-neutralising-monoclonal-antibodies."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/4873\/2533307\/blooda_adv-2026-019978-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/4873\/2533307\/blooda_adv-2026-019978-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:37:18Z","timestamp":1785245838000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/14\/4873\/568092\/Acalabrutinib-monotherapy-as-a-first-line"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":32,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019978","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,28]]},"published":{"date-parts":[[2026,7,15]]}}}